Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.
Daniela CalifanoDaniela GalloGian Luca Rampioni VinciguerraRossella De CecioLaura ArenareSimona SignorielloDaniela RussoGabriella FerrandinaFrancesca CitronNunzia Simona LositoPiera GargiuloVittorio SimeonGiovanni ScambiaSabrina Chiara CecereMarco MontellaNicoletta ColomboGermana TognonEliana BignottiGian Franco ZannoniVincenzo CanzonieriAlessandra CiucciAnna SpinaGiosuè ScognamiglioMichele Del SestoClorinda SchettinoMaria Carmela PiccirilloFrancesco PerronePaolo ChiodiniSandro PignataGustavo BaldassarrePublished in: Cancers (2021)
The analysis of angiogenesis related biomarkers in EOC patients homogenously treated with BEV in first line provides novel insight in their prognostic value and suggests that some of them might merit to be tested as predictive markers of drug activity in dedicated randomized trials.